The average one-year price target for Humacyte (NasdaqGS:HUMA) has been revised to $9.44 / share. This is an increase of 51.64% from the prior estimate of $6.22 dated September 10, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $3.03 to a high of $26.25 / share. The average price target represents an increase of 445.38% from the latest reported closing price of $1.73 / share.
What is the Fund Sentiment?
There are 281 funds or institutions reporting positions in Humacyte. This is an decrease of 7 owner(s) or 2.43% in the last quarter. Average portfolio weight of all funds dedicated to HUMA is 0.02%, an increase of 32.09%. Total shares owned by institutions decreased in the last three months by 3.47% to 65,486K shares. 
The put/call ratio of HUMA is 0.19, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,809K shares representing 2.40% ownership of the company. No change in the last quarter.
CenterBook Partners holds 3,430K shares representing 2.16% ownership of the company. In its prior filing, the firm reported owning 1,423K shares , representing an increase of 58.53%. The firm increased its portfolio allocation in HUMA by 157.79% over the last quarter.
IWM - iShares Russell 2000 ETF holds 3,104K shares representing 1.95% ownership of the company. In its prior filing, the firm reported owning 2,374K shares , representing an increase of 23.52%. The firm increased its portfolio allocation in HUMA by 61.81% over the last quarter.
Geode Capital Management holds 2,949K shares representing 1.86% ownership of the company. In its prior filing, the firm reported owning 2,210K shares , representing an increase of 25.03%. The firm increased its portfolio allocation in HUMA by 45.77% over the last quarter.
Marshall Wace, Llp holds 2,639K shares representing 1.66% ownership of the company. In its prior filing, the firm reported owning 49K shares , representing an increase of 98.15%. The firm increased its portfolio allocation in HUMA by 5,764.47% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
